The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of mannitol.
There are two "class 1" studies, and one "class 2" study, and a large body of "Class 3" data, which can be used to support mannitol. The evidence supporting use of mannitol for ICP control is sufficiently strong to warrant guideline status. Mannitol is effective in reducing ICP, and its use is recommended as a guideline in the management of traumatic intracranial hypertension. Serum osmolalities >320 mOsm and hypovolemia should be avoided. There is some data to suggest that bolus administration is preferable to continuous infusion.
D001930:Brain Injuries / Q000188:drug therapy / Q000503:physiopathology; D006259:Craniocerebral Trauma / Q000188:drug therapy* / Q000503:physiopathology; D004234:Diuretics, Osmotic / Q000627:therapeutic use*; D006801:Humans; D007427:Intracranial Pressure; D016239:MEDLINE; D008353:Mannitol / Q000627:therapeutic use*
D004234:Diuretics, Osmotic; D008353:Mannitol